New 8K out: https://www.sec.gov/Archives/edgar
Post# of 15624
(Total Views: 597)
Posted On: 03/14/2019 5:43:58 PM
Re: Hitbodedut10 #14529
New 8K out:
https://www.sec.gov/Archives/edgar/data/14319...orm8-k.htm
Execution of an agreement to perform a Safety and Pharnacokinetic (PK) study of OWC’s soluble tablet versus Sativex®
OWC Pharmaceutical Research Corp. (“OWC”) is happy to announce the execution of a contract with the Souraski Medical Center Fund in Tel Aviv for performing a Single-Dose, Randomized, Crossover Study to compare the Safety, Tolerability and Pharmacokinetics of OWC’s Medical Grade Cannabis - Orally Disintegrating Tablets (MGC-ODT) with Buccal Sativex®, in Healthy Adult Volunteers. This Clinical Trial Agreement (the “Agreement”) is between One World Cannabis Ltd., a company organized and existing under the laws of Israel and a wholly-owned subsidiary of OWC, and The Medical, Infrastructure and Health Services Fund of the Tel Aviv Medical Center, Israel, and Prof. Jacob Ablin M.D. as the Principal Investigator. The primary objectives of the study are:
1. To investigate the pharmacokinetics profile of THC, 11-OH THC and CBD following a single sublingual dose of MGC-ODT.
2. To compare the pharmacokinetic profiles of THC, THC metabolite 11-hydroxy-THC and CBD following a single administration of the investigational MGC-ODT vs. Sativex® Oromucosal Spray.
3. To monitor and compare the safety and tolerability of the MGC-ODT and Sativex® in the participating subjects.
https://www.sec.gov/Archives/edgar/data/14319...orm8-k.htm
Execution of an agreement to perform a Safety and Pharnacokinetic (PK) study of OWC’s soluble tablet versus Sativex®
OWC Pharmaceutical Research Corp. (“OWC”) is happy to announce the execution of a contract with the Souraski Medical Center Fund in Tel Aviv for performing a Single-Dose, Randomized, Crossover Study to compare the Safety, Tolerability and Pharmacokinetics of OWC’s Medical Grade Cannabis - Orally Disintegrating Tablets (MGC-ODT) with Buccal Sativex®, in Healthy Adult Volunteers. This Clinical Trial Agreement (the “Agreement”) is between One World Cannabis Ltd., a company organized and existing under the laws of Israel and a wholly-owned subsidiary of OWC, and The Medical, Infrastructure and Health Services Fund of the Tel Aviv Medical Center, Israel, and Prof. Jacob Ablin M.D. as the Principal Investigator. The primary objectives of the study are:
1. To investigate the pharmacokinetics profile of THC, 11-OH THC and CBD following a single sublingual dose of MGC-ODT.
2. To compare the pharmacokinetic profiles of THC, THC metabolite 11-hydroxy-THC and CBD following a single administration of the investigational MGC-ODT vs. Sativex® Oromucosal Spray.
3. To monitor and compare the safety and tolerability of the MGC-ODT and Sativex® in the participating subjects.
(0)
(0)